In conclusion, our data show that hepatic O-GlcNAcylation enhances CPS1 catalytic efficiency for ammonia and promotes ureagenesis, thus indicating OGA as a novel therapeutic agent for therapy of both genetic and acquired diseases resulting in hyperammonemia. The gene discussed is OGA; the disease is Hyperammonemia.